Literature DB >> 22593590

Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism?

Bernadette Biondi1, Leonard Wartofsky.   

Abstract

CONTEXT: Levothyroxine therapy is the traditional lifelong replacement therapy for hypothyroid patients. Over the last several years, new evidence has led clinicians to evaluate the option of combined T(3) and T(4) treatment to improve the quality of life, cognition, and peripheral parameters of thyroid hormone action in hypothyroidism. The aim of this review is to assess the physiological basis and the results of current studies on this topic. EVIDENCE ACQUISITION: We searched Medline for reports published with the following search terms: hypothyroidism, levothyroxine, triiodothyronine, thyroid, guidelines, treatment, deiodinases, clinical symptoms, quality of life, cognition, mood, depression, body weight, heart rate, cholesterol, bone markers, SHBG, and patient preference for combined therapy. The search was restricted to reports published in English since 1970, but some reports published before 1970 were also incorporated. We supplemented the search with records from personal files and references of relevant articles and textbooks. Parameters analyzed included the rationale for combination treatment, the type of patients to be selected, the optimal T(4)/T(3) ratio, and the potential benefits of this therapy on symptoms of hypothyroidism, quality of life, mood, cognition, and peripheral parameters of thyroid hormone action. EVIDENCE SYNTHESIS: The outcome of our analysis suggests that it may be time to consider a personalized regimen of thyroid hormone replacement therapy in hypothyroid patients.
CONCLUSIONS: Further prospective randomized controlled studies are needed to clarify this important issue. Innovative formulations of the thyroid hormones will be required to mimic a more perfect thyroid hormone replacement therapy than is currently available.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593590     DOI: 10.1210/jc.2011-3399

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  Is measurement of TT3 by immunoassay reliable at low concentrations? A comparison of the Roche Cobas 6000 vs. LC-MSMS.

Authors:  Likhona Siphe Masika; Zhen Zhao; Steven John Soldin
Journal:  Clin Biochem       Date:  2016-02-12       Impact factor: 3.281

Review 2.  Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.

Authors:  Meritxell Tost; José Antonio Monreal; Antonio Armario; Juan David Barbero; Jesús Cobo; Clemente García-Rizo; Miquel Bioque; Judith Usall; Elena Huerta-Ramos; Virginia Soria; Javier Labad
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

3.  Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal.

Authors:  Benjamin Van Tassell; George F Wohlford; Joyce D Linderman; Sheila Smith; Sahzene Yavuz; Frank Pucino; Francesco S Celi
Journal:  Thyroid       Date:  2019-09-12       Impact factor: 6.568

4.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 5.  Novel thyroid hormones.

Authors:  Riccardo Zucchi; Grazia Rutigliano; Federica Saponaro
Journal:  Endocrine       Date:  2019-07-20       Impact factor: 3.633

6.  An Inverse Relationship Between Weight and Free Thyroxine During Early Gestation Among Women Treated for Hypothyroidism.

Authors:  James E Haddow; Louis M Neveux; Glenn E Palomaki; Geralyn Lambert-Messerlian; Fergal D Malone; Mary E D'Alton
Journal:  Thyroid       Date:  2015-06-23       Impact factor: 6.568

Review 7.  DIAGNOSIS OF ENDOCRINE DISEASE: How reliable are free thyroid and total T3 hormone assays?

Authors:  Kerry J Welsh; Steven J Soldin
Journal:  Eur J Endocrinol       Date:  2016-12       Impact factor: 6.664

Review 8.  Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

Authors:  Manuela Schmidinger; Romano Danesi
Journal:  Oncologist       Date:  2017-11-16

9.  The dynamic pituitary response to escalating-dose TRH stimulation test in hypothyroid patients treated with liothyronine or levothyroxine replacement therapy.

Authors:  Sahzene Yavuz; Joyce D Linderman; Sheila Smith; Xiongce Zhao; Frank Pucino; Francesco S Celi
Journal:  J Clin Endocrinol Metab       Date:  2013-04-12       Impact factor: 5.958

10.  Physician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics.

Authors:  Jacqueline Jonklaas; Eshetu Tefera; Nawar Shara
Journal:  Thyroid       Date:  2018-11       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.